Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFA combined with toripalimab for recurrent hepatocellular carcinoma
ChiCTR1900027807Phase 4Completed
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of toripalimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Disease-free survival. Started Jan 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900027807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027807.